Benitec Biopharma Limited (NASDAQ:BNTC – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $27.00.
BNTC has been the subject of several research analyst reports. Evercore assumed coverage on Benitec Biopharma in a report on Tuesday, May 12th. They issued an “outperform” rating and a $25.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Monday, April 20th. Guggenheim downgraded shares of Benitec Biopharma from a “buy” rating to a “neutral” rating in a report on Wednesday, June 10th. Finally, Wall Street Zen lowered shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th.
Get Our Latest Research Report on Benitec Biopharma
Benitec Biopharma Stock Performance
Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last posted its earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03. On average, research analysts predict that Benitec Biopharma will post -1.04 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its holdings in Benitec Biopharma by 44.5% during the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 904 shares during the period. Truvestments Capital LLC raised its stake in shares of Benitec Biopharma by 156.5% in the fourth quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,339 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of Benitec Biopharma during the 3rd quarter valued at about $79,000. Bank of America Corp DE lifted its position in shares of Benitec Biopharma by 2,255.8% during the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,587 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new position in shares of Benitec Biopharma during the 2nd quarter valued at approximately $80,000. 52.19% of the stock is owned by hedge funds and other institutional investors.
Benitec Biopharma Company Profile
Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.
Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.
Featured Articles
- Five stocks we like better than Benitec Biopharma
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
